当前位置： SCI文献检索 > NEUROLOGY期刊下所有文献 > A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy.

A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy.

Abstract：

OBJECTIVE:To investigate the efficacy and safety of aceneuramic acid extended-release (Ace-ER), a treatment intended to replace deficient sialic acid, in patients with GNE myopathy. METHODS:UX001-CL301 was a phase 3, double-blind, placebo-controlled, randomized, international study evaluating the efficacy and safety of Ace-ER in patients with GNE myopathy. Participants who could walk ≥200 meters in a 6-minute walk test at screening were randomized 1:1, and stratified by sex, to receive Ace-ER 6 g/d or placebo for 48 weeks and assessed every 8 weeks. The primary endpoint was change in muscle strength over 48 weeks measured by upper extremity composite (UEC) score. Key secondary endpoints included change in lower extremity composite (LEC) score, knee extensor strength, and GNE myopathy-Functional Activity Scale (GNEM-FAS) mobility domain score. Safety assessments included adverse events (AEs), vital signs, and clinical laboratory results. RESULTS:Eighty-nine patients were randomized (Ace-ER n = 45; placebo n = 44). Change from baseline to week 48 for UEC score between treatments did not differ (least square mean [LSM] Ace-ER -2.25 kg vs placebo -2.99 kg; LSM difference confidence interval [CI] 0.74 [-1.61 to 3.09]; p = 0.5387). At week 48, there was no significant difference between treatments for the change in key secondary endpoints: LEC LSM difference (CI) -1.49 (-5.83 to 2.86); knee extension strength -0.40 (-2.38 to 1.58); and GNEM-FAS mobility domain score -0.72 (-2.01 to 0.57). Gastrointestinal events were the most common AEs. CONCLUSIONS:Ace-ER was not superior to placebo in improving muscle strength and function in patients with GNE myopathy. CLASSIFICATION OF EVIDENCE:This study provides Class I evidence that for patients with GNE myopathy, Ace-ER does not improve muscle strength compared to placebo.

journal_name

Neurology

journal_title

Neurology

authors

Lochmüller H,Behin A,Caraco Y,Lau H,Mirabella M,Tournev I,Tarnopolsky M,Pogoryelova O,Woods C,Lai A,Shah J,Koutsoukos T,Skrinar A,Mansbach H,Kakkis E,Mozaffar T

doi

10.1212/WNL.0000000000006932

subject

Has Abstract

pub_date

2019-04-30 00:00:00

pages

e2109-e2117

issue

eissn

0028-3878

issn

1526-632X

pii

WNL.0000000000006932

journal_volume

pub_type

杂志文章,多中心研究,随机对照试验

在线工具

A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy.